Loading…
Loading…
EQUITY / NASDAQ · XNCM
BriaCell Therapeutics Corp.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →02/01/2026 – 04/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗4.0422 USD · 0.0545%
Observed: Oct 2, 2026, 7:59 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 4.04 USD · Volume 104,928
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
02/01/2026 – 04/30/2026 · Units
| Metric | 2026 / Quarter 3 | Prior year | Change |
|---|---|---|---|
| Operating profit | -7,620,794 USD | — | — |
| Net income | -7,164,507 USD | — | — |
| Cash and cash equivalents | 6,880,221 USD | — | — |
| Total equity | 23,408,960 USD | — | — |
| Total assets | 27,071,310 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 302/01/2026 – 04/30/2026ConsolidatedUnits · USD | 2026 / Quarter 308/01/2025 – 04/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/31/2026 – 01/31/2026ConsolidatedUnits · USD | 2026 / Quarter 211/01/2025 – 01/31/2026ConsolidatedUnits · USD | 2026 / Quarter 208/01/2025 – 01/31/2026ConsolidatedUnits · USD | 2026 / Quarter 210/31/2025 – 10/31/2025ConsolidatedUnits · USD | 2026 / Quarter 108/01/2025 – 10/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/31/2025 – 07/31/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 6,880,221 USD | — | — | 29,903,628 USD | — | — | 2,714,012 USD | 10,493,808 USD |
| Net incomeIncome statement | -7,164,507 USD | -22,583,892 USD | — | -7,221,820 USD | -15,419,385 USD | — | -8,197,565 USD | — |
| Operating profitIncome statement | -7,620,794 USD | -23,475,003 USD | — | -7,531,266 USD | -15,854,209 USD | — | -8,322,943 USD | — |
| Total assetsBalance sheet | 27,071,310 USD | — | — | 33,594,454 USD | — | — | 13,075,050 USD | 21,649,706 USD |
| Total equityBalance sheet | 23,408,960 USD | — | 30,213,808 USD | 30,213,808 USD | — | 9,350,404 USD | 9,350,404 USD | 17,334,046 USD |
| Capital expendituresCash flow statement | — | 127,049 USD | — | — | — | — | — | — |
| Financing cash flowCash flow statement | — | 27,874,441 USD | — | — | 27,874,441 USD | — | — | — |
| Investing cash flowCash flow statement | — | -8,795,576 USD | — | — | 7,207,473 USD | — | -75,000 USD | — |
| Operating cash flowCash flow statement | — | -22,692,452 USD | — | — | -15,672,094 USD | — | -7,704,796 USD | — |
| Report source | Open report ↗ Published: 06/09/2026 | Open report ↗ Published: 06/09/2026 | Open report ↗ Published: 06/09/2026 | Open report ↗ Published: 03/10/2026 | Open report ↗ Published: 03/10/2026 | Open report ↗ Published: 03/10/2026 | Open report ↗ Published: 12/11/2025 | Open report ↗ Published: 06/09/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.